Noul Co

Noul Co FCF Yield

The Free Cash Flow Yield of Noul Co (376930.KQ) as of Oct 30, 2026 is -25.04 %. In the previous year, Free Cash Flow Yield was -21.79 % — a change of 14.92% (lower).

FCF Yield

-25.04 %

YoY

14.92%

Last updated:

Free Cash Flow Yield of Noul Co is 2025 -25.04 % . Free Cash Flow Yield of Noul Co was 2024 -21.79 % . It decreases by 14.92% lower compared to the previous year.

The Noul Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2019
-4.65 KRW
Jan 1, 2020
-10.55 KRW
Jan 1, 2021
-11.83 KRW
Jan 1, 2022
-17.97 KRW
Jan 1, 2023
-16.56 KRW
Jan 1, 2024
-21.79 KRW
Jan 1, 2025
-25.04 KRW
The Noul Co FCF Yield history
YEARFCF YieldYoY
-25.04 %+14.92%
-21.79 %+31.52%
-16.56 %-7.84%
-17.97 %+51.98%
-11.83 %+12.05%
-10.55 %+126.87%
-4.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Noul Co Stock analysis

What does Noul Co do? Noul Co., Ltd. generates revenue through the manufacture and sale of blood test diagnostic devices utilizing AI algorithms and diagnostic kits. The company offers regular monthly subscriptions via its integrated web-based remote diagnosis system, targeting healthcare providers and medical facilities seeking advanced diagnostic solutions. Its core products include AI-based diagnostic devices and associated kits, sold directly to clinics and hospitals for use in blood testing procedures. The firm's services are designed to enhance diagnostic accuracy and efficiency through remote access and subscription models. The company's primary revenue streams stem from the sale of physical diagnostic devices and diagnostic kits, alongside recurring subscription fees for its web-based remote diagnosis platform. Healthcare institutions and medical professionals form the key customer segments, purchasing both the hardware and ongoing service access. Noul Co., Ltd. focuses on delivering AI-driven diagnostic tools that integrate seamlessly into existing healthcare workflows, emphasizing convenience and technological innovation for its clients. Noul Co., Ltd. operates exclusively within the healthcare diagnostics sector, providing AI-powered blood test solutions that combine hardware sales with subscription-based software services. The business model relies on initial device purchases followed by continuous revenue from monthly subscriptions, creating a sustainable income stream. This approach ensures long-term engagement with healthcare providers while maintaining a focus on cutting-edge diagnostic technology. Noul Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Noul Co stock

Free Cash Flow Yield of Noul Co is -25.04 % in 2025.

Free Cash Flow Yield of Noul Co changed from -21.79 % to -25.04 %, representing a 14.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Noul Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Noul Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Noul Co

All Key Metrics — Noul Co